Full-Time

Head of Operations Inflammation & Immunology

I&I

Posted on 2/1/2025

Pfizer

Pfizer

10,001+ employees

Develops and manufactures vaccines and medicines

Social Impact
Biotechnology
Healthcare

Compensation Overview

$242k - $403.4kAnnually

+ Bonus

Expert

No H1B Sponsorship

Cambridge, MA, USA

Relocation eligible

Category
Project Management
Strategy Development
Business Development
Business & Strategy

You match the following Pfizer's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • MBA and/or PhD in a biomedical discipline
  • Advanced strategic planning, business analysis, communication, and business software skills
  • End-to-end business unit experience
  • 10+ years of experience in life sciences organizational management, strategic, financial, and business planning
Responsibilities
  • Lead operations for the entire end-to-end I&I business.
  • Ensure collaborative and productive interfaces with key business partners (e.g. CSI, Commercial, CD&O).
  • Develop and implement short and long-term business strategies.
  • Coordinate business processes such as annual strategy and operating plans, and portfolio prioritization.
  • Manage operational, laboratory, and clinical budgets in collaboration with various departments.
  • Supervise an operations team to ensure optimal functionality.
  • Oversee laboratory operations including capital expense planning, safety, compliance, and space planning.
  • Design and implement new processes to drive efficient operation of the I&I end-to-end organization.
  • Prepare high-quality presentations and communications for internal stakeholders.
  • Work with People Experience (HR), Strategy, and Finance leads to deliver strategic planning and partnerships.
  • Ensure compliance with all policies, guidelines, and procedures.
  • Track and manage the delivery of portfolio projects and collaborations against goals.
  • Provide advice and guidance to the Chief I&I Officer pertaining to internal and external engagements.
  • Coach and mentor a team of business professionals.
Desired Qualifications
  • Strong evidence of business acumen.
  • Ability to lead complex global teams where resources are not in direct control.
  • Proven ability to develop creative solutions to business challenges.
  • Strong project management skills and the ability to handle multiple tasks simultaneously.
  • High emotional intelligence and strong capability to manage and resolve conflicts.

Pfizer focuses on creating and producing healthcare products, particularly medicines and vaccines. The company conducts extensive research and development to discover new treatments, which are then manufactured and sold globally. Pfizer's products include vaccines, cancer treatments, and other specialized medications. A key aspect of Pfizer's operations is its collaboration with BioNTech to develop a vaccine for COVID-19, showcasing its role in addressing public health challenges. Unlike many competitors, Pfizer emphasizes not only the development of new drugs but also the distribution of vaccines to underserved communities. The company's goal is to enhance global health by expanding its range of effective treatments and ensuring access to its products.

Company Size

10,001+

Company Stage

IPO

Total Funding

$3.8B

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Starboard Value's $1 billion stake may drive strategic changes and increase shareholder value.
  • Pfizer's investment in fibrosis treatments expands its therapeutic areas.
  • Involvement in protein modification research diversifies Pfizer's treatment offerings.

What critics are saying

  • Slowdown in COVID-19 vaccine demand impacts Pfizer's revenue streams.
  • Activist investor Starboard Value may influence Pfizer's strategic decisions.
  • Emerging biotech companies pose a threat to Pfizer's market share in immunotherapy.

What makes Pfizer unique

  • Pfizer's partnership with BioNTech led to a highly effective COVID-19 vaccine.
  • Pfizer invests in AI disease models, enhancing predictive insights for drug development.
  • Pfizer's oncology portfolio is strengthened by investments in TCR-based immunotherapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Business Wire
Jan 16th, 2025
Normunity Closes $75 Million Series B Financing to Advance Lead Drug Program Into the Clinic and Broaden Pipeline of Novel Anti-Cancer Therapies Targeting Untapped Drug Mechanisms

Normunity, a biotechnology company creating novel anti-cancer therapies, today announced that it has closed a Series B financing for $75 million. The

TechCrunch
Oct 23rd, 2024
Promise Bio exits stealth backed by Pfizer and AstraZeneca | TechCrunch

The company has made it easier to test for different protein modifications which are critical to the treatment of autoimmune diseases.

The Wall Street Journal
Oct 7th, 2024
Exclusive | Activist Starboard Value Takes $1 Billion Stake in Pfizer

The drugmaker’s shares have slumped as demand for Covid-19 vaccines and treatments had slowed.

Benzinga
Oct 3rd, 2024
Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®

New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health InvestorsEnara Bio's EDAPT® platform is

Business Wire
Jul 18th, 2024
CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts

CytoReason, a leader in developing computational disease models for predictive insights, announced today it secured an aggregated $80 million from Our

Business News This Week
Feb 23rd, 2024
Colorcon Ventures Invests in Vedanta Biosciences, a Clinical-Stage Microbial Therapeutics Company

Colorcon Ventures joins a prominent list of investors who also participated in Vedanta’s fundraising round, including AXA IM Alts, The AMR Ac

GlobeNewswire
Jan 30th, 2024
COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures

Funds will be used to support the advancement of COUR’s Myasthenia Gravis (MG) and Type 1 Diabetes (T1D) product candidates into Phase 2a clinical...

MarketBeat
Jan 10th, 2024
TIAA Trust National Association Invests $17.55 Million in Pfizer Inc. (NYSE:PFE)

TIAA Trust National Association invests $17.55 million in Pfizer Inc. (NYSE:PFE).

Business Wire
Oct 11th, 2023
Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline

Agomab Therapeutics NV (‘Agomab’) today announced the closing of a $100 million (€94.9 million) Series C financing round led by Fidelity Management &a

Web Capital Riesgo
Oct 11th, 2023
Agomab, participada de Asabys, cierra una Series C de $100M con Fidelity, EQT Life Sciences, Canaan, KKR, Asabys y Pfizer - Webcapitalriesgo

11/10/2023 Nota de prensa GOMAB, PARTICIPADA DE ASABYS, CIERRA UNA SERIES C DE $100M CON FIDELITY, EQT LIFE SCIENCES, CANAAN, KKR, ASABYS Y PFIZER Agomab Therapeutics NV(‘Agomab’) ha anunciado hoy el cierre de una ronda de financiación Serie C de 100 millones de dólares liderada por Fidelity Management & Research Company (FMR), con la participación…

Finsmes
Jul 24th, 2023
Cellcentric Receives $25M Strategic Investment From Pfizer

CellCentric, a Cambridge, UK- and and Manchester, UK-based biotechnology company, received a $25M strategic investment from Pfizer.Pfizer will support the company with its own clinical development program in multiple myeloma (MM) for 2024, alongside ongoing trials in specific haematological malignancies, through its Pfizer Ignite offering.Led by CEO Will West, CellCentric focuses on twin acetyl transferase proteins, p300 and CBP, that act as transcription co-activation factors, and that drive the expression of genes important in cancer progression. The company, which has investigated over 50 epigenetic-related targets as new ways to treat disease, and specifically cancer, was spun out from the University of Cambridge, by pioneering developmental biologist Professor Azim Surani FRS, CBE, who wanted to further explore the potential of epigenetics to deliver new treatments. In June 2023, CellCentric was granted orphan drug and fast track designation status from the FDA for inobrodib.Inobrodib works by binding to a specific part of proteins p300 and CBP (bromodomain). It is highly selective and does not impact similar pockets on other proteins. Through this action inobrodib reduces the expression of key cancer drivers: IRF4, MYC, and the androgen receptor (AR and its variants).In June 2023, CellCentric was granted orphan drug and fast track designation status from the FDA for inobrodib.As part of the collaboration, Astrid Ruefli-Brasse, Vice President, Tumour Biology, Pfizer Worldwide Research Development, will join CellCentric’s Scientific Advisory Board and Sriram Krishnaswami, Vice President and Development Head, Multiple Myeloma, Pfizer Global Product Development, will serve as an advisor to CellCentric.FinSMEs23/07/2023

INACTIVE